Medications like GLP-1 agonists are referred to as incretin mimetics since they mimic these effects How is Semaglutide dosed
to reduce the risk of sustained estimated GFR (eGFR) decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Ozempic and Rybelsus tablets: To reduce the risk of major CV events in patients with type 2 diabetes mellitus who are at high risk for these events Wegovy (injection and tablets): In combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse CV events in patients with established CV disease and either obesity or overweight Usual Adult Dose for Renal Risk Reduction Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: After at least 4 weeks on the 0.5 mg dose, increase to 1 mg subcutaneously once a week
Metsera has a nice slide on this below, and assuming their calculations are true, this COGs delta could prove to be a valuable commercial advantage
calorie consumption by about 1.6 percent by 2035
Pharmacological stimuli are not physiological, and their accuracy is poor
It comes from how these drugs change the way you eat, hydrate, and move blood